New Bunion Treatments Will Open Broader Market Opportunities

Shared on01 May 25
Fair value Decreased 11%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 1.87%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 16%

AnalystConsensusTarget has increased future PE multiple from 21.3x to 25.2x and decreased shares outstanding growth rate from 0.0% to 0.0%.

Shared on02 Apr 25
Fair value Decreased 3.06%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.